ASH 2018 | IDH1/2 inhibitors for upfront AML therapy and transfusion independence
Amir Fathi
• 6 Dec 2018
Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Amir Fathi, MD, MPH, of the Massachusetts General Hospital, Boston, MA, discusses the investigation of ivosidenib or enasidenib plus consolidation chemotherapy in newly diagnosed acute myeloid leukemia patients with IDH1 or IDH2 mutations (NCT02632708). He also covers the promise of IDH1 inhibitors for giving transfusion independence.
